Joseph Stringer
Stock Analyst at Needham
(3.21)
# 1,155
Out of 4,412 analysts
176
Total ratings
37.36%
Success rate
3.68%
Average return
Main Sectors:
Top Industries:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHAT Phathom Pharmaceuticals | Reiterates: Buy | $26 | $9.18 | +183.22% | 23 | Apr 26, 2024 | |
| RYTM Rhythm Pharmaceuticals | Reiterates: Buy | $50 | $38.28 | +30.62% | 13 | Apr 26, 2024 | |
| GILD Gilead Sciences | Reiterates: Hold | n/a | $65.42 | - | 1 | Apr 26, 2024 | |
| CDTX Cidara Therapeutics | Maintains: Buy | $3 → $25 | $12.63 | +97.94% | 6 | Apr 25, 2024 | |
| APLS Apellis Pharmaceuticals | Reiterates: Buy | $85 | $49.86 | +70.48% | 13 | Apr 25, 2024 | |
| LXRX Lexicon Pharmaceuticals | Reiterates: Hold | n/a | $1.58 | - | 3 | Apr 23, 2024 | |
| MRNA Moderna | Reiterates: Hold | n/a | $107.97 | - | 2 | Apr 11, 2024 | |
| RNA Avidity Biosciences | Reiterates: Buy | $35 | $24.36 | +43.68% | 9 | Apr 11, 2024 | |
| ANNX Annexon | Reiterates: Buy | $16 | $4.70 | +240.43% | 13 | Apr 11, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Buy | $22 | $12.41 | +77.28% | 12 | Apr 11, 2024 | |
| PCVX Vaxcyte | Reiterates: Buy | $95 | $60.72 | +56.46% | 7 | Apr 10, 2024 | |
| PLRX Pliant Therapeutics | Reiterates: Buy | $38 | $11.81 | +221.76% | 11 | Apr 10, 2024 | |
| INZY Inozyme Pharma | Reiterates: Buy | $23 | $4.44 | +418.02% | 12 | Apr 10, 2024 | |
| CARA Cara Therapeutics | Reiterates: Buy | $5 | $0.68 | +630.67% | 12 | Apr 10, 2024 | |
| IONS Ionis Pharmaceuticals | Reiterates: Buy | $60 | $41.59 | +44.27% | 11 | Apr 9, 2024 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Buy | $200 | $143.31 | +39.56% | 11 | Feb 15, 2024 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $37 | $16.71 | +121.42% | 4 | Jan 24, 2024 | |
| VIR Vir Biotechnology | Maintains: Buy | $22 → $15 | $8.23 | +82.26% | 11 | Nov 3, 2023 | |
| TBPH Theravance Biopharma | Maintains: Buy | n/a | $9.12 | - | 2 | Aug 24, 2021 |
Phathom Pharmaceuticals
Apr 26, 2024
Reiterates: Buy
Price Target: $26
Current: $9.18
Upside: +183.22%
Rhythm Pharmaceuticals
Apr 26, 2024
Reiterates: Buy
Price Target: $50
Current: $38.28
Upside: +30.62%
Gilead Sciences
Apr 26, 2024
Reiterates: Hold
Price Target: n/a
Current: $65.42
Upside: -
Cidara Therapeutics
Apr 25, 2024
Maintains: Buy
Price Target: $3 → $25
Current: $12.63
Upside: +97.94%
Apellis Pharmaceuticals
Apr 25, 2024
Reiterates: Buy
Price Target: $85
Current: $49.86
Upside: +70.48%
Lexicon Pharmaceuticals
Apr 23, 2024
Reiterates: Hold
Price Target: n/a
Current: $1.58
Upside: -
Moderna
Apr 11, 2024
Reiterates: Hold
Price Target: n/a
Current: $107.97
Upside: -
Avidity Biosciences
Apr 11, 2024
Reiterates: Buy
Price Target: $35
Current: $24.36
Upside: +43.68%
Annexon
Apr 11, 2024
Reiterates: Buy
Price Target: $16
Current: $4.70
Upside: +240.43%
Stoke Therapeutics
Apr 11, 2024
Reiterates: Buy
Price Target: $22
Current: $12.41
Upside: +77.28%
Vaxcyte
Apr 10, 2024
Reiterates: Buy
Price Target: $95
Current: $60.72
Upside: +56.46%
Pliant Therapeutics
Apr 10, 2024
Reiterates: Buy
Price Target: $38
Current: $11.81
Upside: +221.76%
Inozyme Pharma
Apr 10, 2024
Reiterates: Buy
Price Target: $23
Current: $4.44
Upside: +418.02%
Cara Therapeutics
Apr 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.68
Upside: +630.67%
Ionis Pharmaceuticals
Apr 9, 2024
Reiterates: Buy
Price Target: $60
Current: $41.59
Upside: +44.27%
Alnylam Pharmaceuticals
Feb 15, 2024
Reiterates: Buy
Price Target: $200
Current: $143.31
Upside: +39.56%
ACADIA Pharmaceuticals
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $16.71
Upside: +121.42%
Vir Biotechnology
Nov 3, 2023
Maintains: Buy
Price Target: $22 → $15
Current: $8.23
Upside: +82.26%
Theravance Biopharma
Aug 24, 2021
Maintains: Buy
Price Target: n/a
Current: $9.12
Upside: -